Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 558

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

Open access
Parry, David, Guzi, Timothy, Shanahan, Frances, Davis, Nicole, Prabhavalkar, Deepa, Wiswell, Derek, Seghezzi, Wolfgang, Paruch, Kamil, Dwyer, Michael P., Doll, Ronald, Nomeir, Amin, Windsor, William, Fischmann, Thierry, Wang, Yaolin, Oft, Martin, Chen, Taiying, Kirschmeier, Paul, Lees, Emma M. · 2010 · Molecular Cancer Therapeutics

Abstract

Cyclin-dependent kinases (CDK) are key positive regulators of cell cycle progression and attractive targets in oncology. SCH 727965 inhibits CDK2, CDK5, CDK1, and CDK9 activity in vitro with IC50 values of 1, 1, 3, and 4 nmol/L, respectively. SCH 727965 was selected as a clinical candidate using a functional screen in vivo that integrated both efficacy and safety parameters. Compared with flavopiridol, SCH 727965 exhibits superior activity with an improved therapeutic index. In cell-based assays, SCH 727965 completely suppressed retinoblastoma phosphorylation, which correlated with apoptosis onset and total inhibition of bromodeoxyuridine incorporation in >100 tumor cell lines of diverse origin and background. Moreover, short exposures to SCH 727965 were sufficient for long-lasting cellular effects. SCH 727965 induced regression of established solid tumors in a range of mouse models following intermittent scheduling of doses below the maximally tolerated level. This was associated with modulation of pharmacodynamic biomarkers in skin punch biopsies and rapidly reversible, mechanism-based effects on hematologic parameters. These results suggest that SCH 727965 is a potent and selective CDK inhibitor and a novel cytotoxic agent. Mol Cancer Ther; 9(8); 2344–53. ©2010 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-10-0324

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 558

Metadata

Authors
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., Nomeir, A., Windsor, W., Fischmann, T., Wang, Y., Oft, M., Chen, T., Kirschmeier, P., & Lees, E. M.
Venue
Molecular Cancer Therapeutics
Published
2010-08-01
Volume
9
Issue
8
Pages
2344-2353
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2140642045
Cited by
558
References
19
FWCI
7.98
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor. https://app.cochat.ai/papers/10.1158/1535-7163.mct-10-0324
The paper
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., Nomeir, A., Windsor, W., Fischmann, T., Wang, Y., Oft, M., Chen, T., Kirschmeier, P., & Lees, E. M. (2010). Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-10-0324

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.